The Florida Gators pick up a veteran guard through the transfer portal with multiple connections to the program ...

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis ...

The Business Research Company The Business Research Company's Ocrevus Global Market Report 2025 – Market Size, Trends, And Global Forecast ...

Ocrevus (ocrelizumab) has potential interactions with other medications and some vaccines. These interactions could affect how well the drug works or cause harmful effects.

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis ...

Ocrevus Zunovo is the first and only twice-yearly, 10-minute subcutaneous injection for treating both relapsing multiple sclerosis and primary-progressive multiple sclerosis.

SOUTH SAN FRANCISCO, Calif., September 13, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has ...

The FDA has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing forms of multiple sclerosis.

This article discusses pregnancy and breastfeeding information related to Ocrevus. To learn more about Ocrevus that’s unrelated to pregnancy and breastfeeding, see this article.

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...